Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effects of cardiovascular disease on pharmacokinetics.

Literature DB >> 2577313

Effects of cardiovascular disease on pharmacokinetics.

Abstract

The pathophysiologic changes occurring in cardiovascular disease can affect the kinetics of drugs in several different ways. The present review examines these modifications and the underlying mechanisms. The kinetics of specific agents, such as antiarrhythmic, antihypertensive, cardiotonic, and other drugs are considered, and the clinical implications are outlined. The clinician should be aware of these modifications, because they require an adjustment of the dosage regimen. A rational basis for a correct therapeutic choice can be provided by adequate knowledge of these modifications.

Entities: Disease

Mesh：

Substances：

Year: 1989 PMID： 2577313 DOI： 10.1007/bf01857622

Source DB: PubMed Journal: Cardiovasc Drugs Ther ISSN： 0920-3206 Impact factor: 3.727

147 in total

1. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine.

Authors: D R Robertson; D G Waller; A G Renwick; C F George
Journal: Br J Clin Pharmacol Date: 1988-03 Impact factor: 4.335

2. Cyclosporine kinetics in pediatric patients with congestive heart failure.

Authors: G J Burckart; F J Fricker; R Venkataramanan; R J Ptachcinski; R L Hardesty; A Trento; D L Howrie; B P Griffith
Journal: Transplant Proc Date: 1987-02 Impact factor: 1.066

3. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.

Authors: P D Thomson; K L Melmon; J A Richardson; K Cohn; W Steinbrunn; R Cudihee; M Rowland
Journal: Ann Intern Med Date: 1973-04 Impact factor: 25.391

4. Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man.

Authors: R E Stenson; R T Constantino; D C Harrison
Journal: Circulation Date: 1971-02 Impact factor: 29.690

5. Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure.

Authors: J R Benotti; L J Lesko; J E McCue; J S Alpert
Journal: Am J Cardiol Date: 1985-10-01 Impact factor: 2.778

6. Prazosin plasma concentration and blood pressure reduction.

Authors: P Larochelle; P du Souich; P Hamet; P Larocque; J Armstrong
Journal: Hypertension Date: 1982 Jan-Feb Impact factor: 10.190

7. Prazosin kinetics in essential hypertension.

Authors: N P Chau; B L Flouvat; E Le Roux; M E Safar
Journal: Clin Pharmacol Ther Date: 1980-07 Impact factor: 6.875

8. Cirrhosis of the liver markedly impairs the elimination of mexiletine.

Authors: P J Pentikäinen; S Hietakorpi; M O Halinen; L M Lampinen
Journal: Eur J Clin Pharmacol Date: 1986 Impact factor: 2.953

9. Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment.

Authors: R Larsson; H Liedholm; K E Andersson; M A Keane; G Henry
Journal: Eur J Clin Pharmacol Date: 1986 Impact factor: 2.953

10. Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure.

Authors: J Bonde; H R Angelo; S Bødtker; T L Svendsen; J P Kampmann
Journal: Acta Pharmacol Toxicol (Copenh) Date: 1985-04

3 in total

1. Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly.

Authors: Felix Stader; Hannah Kinvig; Melissa A Penny; Manuel Battegay; Marco Siccardi; Catia Marzolini
Journal: Clin Pharmacokinet Date: 2020-03 Impact factor: 6.447

Review 2. Antiarrhythmics: elimination and dosage considerations in hepatic impairment.

Authors: Ulrich Klotz
Journal: Clin Pharmacokinet Date: 2007 Impact factor: 6.447

3. Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.

Authors: Lisa Alina Kneller; Georg Hempel
Journal: Pharm Res Date: 2020-05-31 Impact factor: 4.200

3 in total